Adenoviral production of interleukin‐2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy
Explore this paper's citation graph
Summary
Local IL‐2 production results in efficacy and safety gains in the context of ACT in hamsters and mice, and provides the rationale for ongoing clinical translation.
- Type
- article
- Published
- 2017-10-01
- Cited by
- 20
- References
- 52
- Access
- Open access
- OpenAlex
- https://openalex.org/W2626965243
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3576397
Keywords
Medicine, Adoptive cell transfer, Systemic administration, Cancer research, Cell therapy
References
- Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir
- Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors
- Macrophage Polarization in Virus-Host Interactions
- Comparison of vascular leak syndrome in mice treated with IL21 or IL2.
- Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy
- Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.
- Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
- B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice
- IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
- Adoptive cell transfer as personalized immunotherapy for human cancer
- Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
- Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion.
- High-dose Interleukin-2 for the Treatment of Metastatic Renal Cell Carcinoma
- Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma
- Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation
- Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
- A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer
- Deregulated TCR alpha beta T cell population provokes extramedullary hematopoiesis in mice deficient in the common gamma chain.
- AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study.
- The role of interleukin-2 during homeostasis and activation of the immune system
Cited by
- TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
- Vitamin D aggravates breast cancer by inducing immunosuppression in the tumor bearing mouse.
- Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
- Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
- Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
- Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition.
- Development of oncolytic virotherapy: from genetic modification to combination therapy
- Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
- Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
- Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control
- Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
- Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy
- Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses
- Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting
- Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy
- Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy
- Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma
- Reinvigorating the Cancer‐Immunity Cycle With Combined Oncolytic Virus and CAR‐T Cell Therapies in Solid Tumors
Related papers
- Photoactivatable oncolytic adenovirus for optogenetic cancer therapy
- Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.
- Oncolytic adenovirus based on serotype 3
- Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
- Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model
- Gene therapy for oral squamous cell carcinoma with IAI.3B promoter-driven oncolytic adenovirus-infected carrier cells.
- Intratumoral delivery of a Tim-3 antibody-encoding oncolytic adenovirus engages an effective antitumor immune response in liver cancer
- Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy
- Oncolytic adenoviruses for the treatment of brain tumors.